Navigation Links
Cell Genesys to Present at the BIO CEO and Investor Conference
Date:2/4/2008

SOUTH SAN FRANCISCO, Calif., Feb. 4 /PRNewswire-FirstCall/ -- Cell Genesys, Inc. (Nasdaq: CEGE) today announced that Stephen A. Sherwin, M.D., chairman and chief executive officer of Cell Genesys, will present a company update at the BIO CEO and Investor Conference in New York, New York, on Monday, February 11, 2008 at 11:00 a.m. ET.

A live audio webcast of the presentation will be accessible through the Investor Relations section of the Cell Genesys website, http://www.cellgenesys.com. If you are unable to listen to the live webcast, it will be archived on the site for at least 72 hours following the presentation. To access the replay, go to the Investor Relations section of the website.

Cell Genesys is focused on the development and commercialization of novel biological therapies for patients with cancer. The company is currently pursuing two clinical stage product platforms -- GVAX(TM) cancer immunotherapies and oncolytic virus therapies. Ongoing clinical trials include Phase 3 trials of GVAX immunotherapy for prostate cancer, Phase 2 trials of GVAX immunotherapies for pancreatic cancer and for leukemia, and a Phase 1 trial of CG0070 oncolytic virus therapy for bladder cancer. Cell Genesys continues to hold an equity interest in its former subsidiary, Ceregene, Inc., which is developing gene therapies for neurodegenerative disorders. Cell Genesys is headquartered in South San Francisco, CA and has its principal manufacturing operation in Hayward, CA. For additional information, please visit the company's website at http://www.cellgenesys.com.

Contact:

Susan Ferris

Investor Relations'/>"/>

SOURCE Cell Genesys
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Cell Genesys to Present at the Bear Stearns 20th Annual Healthcare Conference
2. Cell Genesys to Present at the BIO Investor Forum
3. Cell Genesys to Webcast Third Quarter 2007 Conference Call
4. Cell Genesys Announces Sale of Lentiviral Gene Delivery Technology for $12 Million
5. Imagenetix Inc. to Present at Noble Small Cap Financial Conference on August 21, 2007
6. Avicena Group to Present at Noble Financial Conference
7. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
8. Strategic Diagnostics to Present at Two Upcoming Investor Conferences
9. Intellect Neurosciences, Inc. to Present Data on Alzheimers Vaccine at 13th International Congress of Immunology Conference
10. CEL-SCI to Present at the Noble Financial Conference
11. Lexicon Presents Class of Compounds Modulating TPH1, the Target for its LX1031 Investigational Drug for Irritable Bowel Syndrome
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2015)... April 28, 2015 IMS is ... bring it to the web and provide greater ... user friendly reporting metrics increase data warehouse’s utility; ... convenient recall and access “on-the-go” makes data analysis ... using client feedback to assist in repository analytics ...
(Date:4/28/2015)... Reproductive endocrinologist Dr. Kaylen Silverberg , ... battling infertility in this country, testified on behalf of ... first state in the nation to consider creating a clearinghouse ... who desire to receive them. , Infertility affects over 7.3 ... is one of the few medical diseases that is curable, ...
(Date:4/27/2015)... 27, 2015 Dr. Robert Hanzlik, whose ... toxicity carries implications for advancing the creation of safer ... National University , the second-largest private, nonprofit university ... Hanzlik, a professor at the University of Kansas School ... design, starts at 5 p.m. and takes place at ...
(Date:4/27/2015)... Kan. , April 27, 2015   ... a pet therapeutics company focused on the licensing, ... companion animals, today provided commentary on clinical study ... during a poster session at the American Association ... ADXS31-164 is a novel Lm -LLO ...
Breaking Biology Technology:Texas Fertility Center Supports a Groundbreaking HB1145 that Facilitates Embryo Donation in Texas 2Texas Fertility Center Supports a Groundbreaking HB1145 that Facilitates Embryo Donation in Texas 3Dr. Robert Hanzlik Discusses Pharmaceutical Testing Models at Event Hosted by National University 2Dr. Robert Hanzlik Discusses Pharmaceutical Testing Models at Event Hosted by National University 3Aratana Therapeutics Comments on ADXS31-164 (AT-014) Study Data Presented During Poster Session at the American Association for Cancer Research (AACR) Annual Meeting 2015 2
... TorreyPines Therapeutics, Inc. (Nasdaq: TPTX ) ... the Southern District of New York dismissed proceedings filed ... ("Axonyx") against Axonyx and several of Axonyx,s former directors ... plaintiffs alleged that the defendants made misleading statements related ...
... Enterprises, Inc. (BME), a rapidly growing medical device company ... implants, announced today that it has appointed Keith M. ... BME specializes in nitinol implants that contract and compress ... bone union. The O rthopaedic S ...
... Cell Trial to Show Dose-related Significant Improvement in Perfusion ... Amorcyte, Inc. (Amorcyte) today announced data from its Phase ... for the treatment of damaged heart muscle following acute ... cell dose and biologic effect. This is the first ...
Cached Biology Technology:Stockholder Suits Related to TorreyPines Therapeutics, Inc. Dismissed 2BioMedical Enterprises, Inc. (BME) Announces the Appointment of Keith M. Peeples as Vice President, Sales and Marketing 2Amorcyte Reports Phase I Results of AMR-001 to Improve Recovery From Severe Heart Attack at ACC Annual Scientific Session 2Amorcyte Reports Phase I Results of AMR-001 to Improve Recovery From Severe Heart Attack at ACC Annual Scientific Session 3Amorcyte Reports Phase I Results of AMR-001 to Improve Recovery From Severe Heart Attack at ACC Annual Scientific Session 4
(Date:3/31/2015)... , March 31, 2015   Guidepoint , ... launch of the Post-Surgical Pain Management TRACKER, part of ... tracking usage trends in the medical device and therapeutics ... to data including treatment volumes, market share, and adoption ... pain associated with joint surgery. The Post-Surgical ...
(Date:3/24/2015)... 24, 2015   NexID Biometrics LLC, whose ... needs, today announced the beginning of shipments of version ... The company, based in Potsdam, N.Y. ... Connect:ID Expo, which began here today at the Walter ... 2.0 of its SDK boosts the accuracy rate range ...
(Date:3/23/2015)... , Mar. 23, 2015 NXT-ID, Inc. (NASDAQ: ... focused on the growing mobile commerce market, announces its biometric ... advertising campaign on CNBC television starting March 30 th ... commence airing in New York markets. ... said: "We are excited about our new ad campaign following ...
Breaking Biology News(10 mins):Guidepoint Launches Post-Surgical Pain Management TRACKER 2Guidepoint Launches Post-Surgical Pain Management TRACKER 3NexID Begins Shipments Of Version 2.0 Fake-Finger-Detection Solution 2NXT-ID's Wocket Smart Wallet to Launch New CNBC Regional TV Ad Campaign 2NXT-ID's Wocket Smart Wallet to Launch New CNBC Regional TV Ad Campaign 3
... A component of DNA that can both stimulate ... may hold hope for treating cancer and infection, Medical ... of CpG increase inflammation, part of the body,s way ... increasing expression of the enzyme indoleamine 2,3 dioxygenase, or ...
... A new study by researchers at Princeton University,s Woodrow ... that global climate change may lead to the retreat ... States, which could create unprecedented ecological restoration opportunities across ... time, global warming may enable other invasive plants to ...
... a surprising link between brain iron levels and ... from autism to major depression., Appearing in the ... this week, the study by Randy Blakely, ... a powerful in silico approach for discovering novel ...
Cached Biology News:DNA component can stimulate and suppress the immune response 2Climate change's impact on invasive plants in Western US may create restoration opportunities 2Climate change's impact on invasive plants in Western US may create restoration opportunities 3Climate change's impact on invasive plants in Western US may create restoration opportunities 4Researchers iron out new role for serotonin 2
... Streptavidin-Horseradish Peroxidase Conjugate, 2 ... reporter enzyme molecules for ... in situ hybridization applications.High ... & Labeling & Detection, ...
...
normal rat IgM AF647...
Chicken anti-EEA1...
Biology Products: